C
AVBP icon

Covestor’s ArriVent BioPharma AVBP Stock Holding History

Covestor’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
13
+4
+44% +$118 ﹤0.01% 2893
2026
Q1 		$0 Sell
9
-1
-10% -$23 ﹤0.01% 2848
2025
Q4 		$0 Sell
10
-1
-9% -$21 ﹤0.01% 2817
2025
Q3 		$0 Buy
11
+7
+175% +$138 ﹤0.01% 2862
2025
Q2 		$0 Hold
4
– – ﹤0.01% 2833
2025
Q1 		$0 Buy
+4
New +$98 ﹤0.01% 2804

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Covestor's AVBP Position: Q2 2026 in Review

Covestor increased its ArriVent BioPharma (AVBP) stake by 44% in Q2 2026, buying an estimated $118 and bringing the position to 13 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2893.

Covestor first reported a position in AVBP in Q1 2025 and has held it in 6 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Covestor held 13 shares of ArriVent BioPharma worth $0 as of Q2 2026.
  • Covestor bought 4 ArriVent BioPharma shares in Q2 2026, an estimated $118.
  • ArriVent BioPharma made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2893 holding.
  • Covestor first reported a position in ArriVent BioPharma in Q1 2025 and has held it in 6 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.